Pfizer, Lilly Weigh In On Dosing And Safety Of Non-Opioid Pain Drug Tanezumab
Two dosing regimens hit the mark on three co-primary endpoints and the rate of rapidly progressive osteoarthritis was low at 1.3% in a Phase III study of the NGF inhibitor presented on Oct. 23.
You may also be interested in...
The companies reported positive Phase III data testing the nerve growth factor inhibitor in patients with chronic pain, but the efficacy appears modest and safety will remain a question until long-term Phase III data read out. The companies are focused on a lower 1 mg dose.
Pfizer and Lilly said tanezumab reduced pain in a Phase III osteoarthritis study, but safety is the biggest question for NGF inhibitors. Yet, while Regeneron and Teva discontinued dosing for their fasinumab at its highest dose, tanezumab was effective at both doses in its first Phase III test.
Pfizer is abandoning research to find new drugs for Alzheimer’s and Parkinson’s disease, realizing that finding treatments for the diseases is very tough - but M&A could allow an eventual return, analysts say.